600566.SS
Hubei Jumpcan Pharmaceutical Co., Ltd. [600566.SS] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
600566.SS Stock Summary
Top 10 Correlated ETFs
600566.SS
Top 10 Correlated Stocks
600566.SS
In the News
600566.SS Financial details
Company Rating
Strong Buy
Market Cap
38.35B
Income
2.82B
Revenue
9.61B
Book val./share
14.57
Cash/share
11.91
Dividend
0.88
Dividend %
2.7%
Employees
5.23K
Optionable
No
Shortable
Yes
Earnings
20 Apr 2024
P/E
11.85
Forward P/E
-
PEG
4.52
P/S
3.09
P/B
2.4
P/C
3.69
P/FCF
31.25
Quick Ratio
3.12
Current Ratio
3.27
Debt / Equity
0.12
LT Debt / Equity
0
-
-
EPS (TTM)
3.08
EPS next Y
-
EPS next Q
-
EPS this Y
26.23%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
9.13%
Revenue last 5Y
6.5%
Revenue Q/Q
60.98%
EPS Q/Q
45.45%
-
-
-
-
SMA20
13.51%
SMA50
35.48%
SMA100
50%
Inst Own
-
Inst Trans
-
ROA
15%
ROE
21%
ROC
0.23%
Gross Margin
82%
Oper. Margin
30%
Profit Margin
26%
Payout
32%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
23.95-42.31
52W High
+4.67%
52W Low
+91.13%
RSI
83
Rel Volume
1.36
Avg Volume
6.8M
Volume
9.25M
Perf Week
9.22%
Perf Month
14.72%
Perf Quarter
70.06%
Perf Half Y
67.59%
-
-
-
-
Beta
0.164
-
-
Volatility
0.93%, 2.77%
Prev Close
0%
Price
43.96
Change
-0.2%
600566.SS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 8.52 | 7.39 | 8.59 | 10.11 | 10.38 | |
| Net income per share | 1.99 | 1.53 | 1.94 | 2.44 | 3.08 | |
| Operating cash flow per share | 2.64 | 2.13 | 2.13 | 2.95 | 3.87 | |
| Free cash flow per share | 1.96 | 1.62 | 1.85 | 2.67 | 3.54 | |
| Cash per share | 3.04 | 5.05 | 6.19 | 8.84 | 11.91 | |
| Book value per share | 7.49 | 9.3 | 10.26 | 12.74 | 14.57 | |
| Tangible book value per share | 6.87 | 8.76 | 9.78 | 12.21 | 14.14 | |
| Share holders equity per share | 7.49 | 9.3 | 10.26 | 12.74 | 14.57 | |
| Interest debt per share | 0.75 | 0.76 | 0.75 | 0.48 | 1.75 | |
| Market cap | 19.7B | 16.89B | 25.17B | 24.22B | 30.52B | |
| Enterprise value | 18B | 14.53B | 21.98B | 19.8B | 24.36B | |
| P/E ratio | 12.14 | 13.22 | 14.64 | 11.16 | 10.81 | |
| Price to sales ratio | 2.84 | 2.74 | 3.3 | 2.69 | 3.21 | |
| POCF ratio | 9.17 | 9.48 | 13.29 | 9.24 | 8.61 | |
| PFCF ratio | 12.31 | 12.49 | 15.29 | 10.19 | 9.41 | |
| P/B Ratio | 3.23 | 2.18 | 2.76 | 2.14 | 2.29 | |
| PTB ratio | 3.23 | 2.18 | 2.76 | 2.14 | 2.29 | |
| EV to sales | 2.59 | 2.36 | 2.88 | 2.2 | 2.56 | |
| Enterprise value over EBITDA | 8.35 | 8.07 | 9.61 | 6.91 | 7.64 | |
| EV to operating cash flow | 8.38 | 8.16 | 11.61 | 7.55 | 6.87 | |
| EV to free cash flow | 11.24 | 10.75 | 13.36 | 8.33 | 7.51 | |
| Earnings yield | 0.08 | 0.08 | 0.07 | 0.09 | 0.09 | |
| Free cash flow yield | 0.08 | 0.08 | 0.07 | 0.1 | 0.11 | |
| Debt to equity | 0.09 | 0.08 | 0.07 | 0.04 | 0.12 | |
| Debt to assets | 0.07 | 0.06 | 0.05 | 0.03 | 0.09 | |
| Net debt to EBITDA | -0.79 | -1.31 | -1.39 | -1.54 | -1.93 | |
| Current ratio | 2.67 | 3.34 | 2.9 | 3.26 | 3.1 | |
| Interest coverage | 60.44 | 44.47 | 55.38 | 79.7 | 164.04 | |
| Income quality | 1.32 | 1.39 | 1.1 | 1.21 | 1.26 | |
| Dividend Yield | 0.05 | 0.06 | 0.02 | 0.03 | 0.03 | |
| Payout ratio | 0.62 | 0.79 | 0.24 | 0.28 | 0.29 | |
| Sales general and administrative to revenue | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.03 | 0.04 | 0.07 | 0.06 | 0.04 | |
| Intangibles to total assets | 0.06 | 0.04 | 0.04 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.25 | -0.24 | -0.13 | -0.09 | -0.09 | |
| Capex to revenue | -0.08 | -0.07 | -0.03 | -0.03 | -0.03 | |
| Capex to depreciation | -2.35 | -1.53 | -0.85 | -0.79 | -0.99 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | -0.02 | |
| Graham number | 18.32 | 17.89 | 21.14 | 26.45 | 31.77 | |
| ROIC | 0.24 | 0.15 | 0.17 | 0.18 | 0.17 | |
| Return on tangible assets | 0.2 | 0.13 | 0.15 | 0.15 | 0.16 | |
| Graham Net | 2.02 | 3.78 | 4.91 | 7.43 | 9.34 | |
| Working capital | 3.07B | 4.61B | 5.32B | 7.75B | 9.64B | |
| Tangible asset value | 5.6B | 7.31B | 8.68B | 10.86B | 12.96B | |
| Net current asset value | 2.35B | 3.82B | 5.12B | 7.55B | 9.53B | |
| Invested capital | 0.09 | 0.08 | 0.07 | 0.04 | 0.12 | |
| Average receivables | 2.12B | 2.08B | 2.16B | 2.57B | 2.86B | |
| Average payables | 683.6M | 732.27M | 853.52M | 1.23B | 1.6B | |
| Average inventory | 328.32M | 308.45M | 327.01M | 383.53M | 440.78M | |
| Days sales outstanding | 109.83 | 122.58 | 107.24 | 117.92 | 107.62 | |
| Days payables outstanding | 231.21 | 245.84 | 270.42 | 357.36 | 323.9 | |
| Days of inventory on hand | 111.28 | 89.91 | 107.39 | 92.94 | 93.68 | |
| Receivables turnover | 3.32 | 2.98 | 3.4 | 3.1 | 3.39 | |
| Payables turnover | 1.58 | 1.48 | 1.35 | 1.02 | 1.13 | |
| Inventory turnover | 3.28 | 4.06 | 3.4 | 3.93 | 3.9 | |
| ROE | 0.27 | 0.16 | 0.19 | 0.19 | 0.21 | |
| Capex per share | -0.67 | -0.51 | -0.28 | -0.27 | -0.33 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 3.47 | 2.61 | 2.45 | 2.08 | 3.35 | |
| Net income per share | 0.65 | 0.74 | 0.72 | 0.66 | 0.96 | |
| Operating cash flow per share | 0.65 | 0.74 | 1 | 0.75 | 0.67 | |
| Free cash flow per share | 0.58 | 0.68 | 0.92 | 0.63 | 0.6 | |
| Cash per share | 8.8 | 9.99 | 10.74 | 11.06 | 11.91 | |
| Book value per share | 12.69 | 13.12 | 12.97 | 13.62 | 14.57 | |
| Tangible book value per share | 12.16 | 12.62 | 12.47 | 13.12 | 14.14 | |
| Share holders equity per share | 12.69 | 13.12 | 12.97 | 13.62 | 14.57 | |
| Interest debt per share | 0.45 | 0.44 | 0.61 | 0.88 | 1.74 | |
| Market cap | 24.32B | 26.08B | 26.59B | 25.03B | 30.52B | |
| Enterprise value | 19.9B | 19.01B | 18.9B | 18.15B | 24.36B | |
| P/E ratio | 10.51 | 9.63 | 10.03 | 10.35 | 8.68 | |
| Price to sales ratio | 7.84 | 10.92 | 11.87 | 13.12 | 9.94 | |
| POCF ratio | 42.03 | 38.54 | 28.93 | 36.48 | 49.94 | |
| PFCF ratio | 47.24 | 41.95 | 31.45 | 43.4 | 55.74 | |
| P/B Ratio | 2.15 | 2.17 | 2.24 | 2.01 | 2.29 | |
| PTB ratio | 2.15 | 2.17 | 2.24 | 2.01 | 2.29 | |
| EV to sales | 6.41 | 7.96 | 8.44 | 9.51 | 7.93 | |
| Enterprise value over EBITDA | 28.09 | 25.47 | 24.2 | 26.55 | 24.18 | |
| EV to operating cash flow | 34.39 | 28.1 | 20.56 | 26.46 | 39.87 | |
| EV to free cash flow | 38.66 | 30.58 | 22.36 | 31.48 | 44.49 | |
| Earnings yield | 0.02 | 0.03 | 0.02 | 0.02 | 0.03 | |
| Free cash flow yield | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | |
| Debt to equity | 0.04 | 0.03 | 0.05 | 0.06 | 0.12 | |
| Debt to assets | 0.03 | 0.03 | 0.03 | 0.05 | 0.09 | |
| Net debt to EBITDA | -6.24 | -9.47 | -9.85 | -10.05 | -6.11 | |
| Current ratio | 3.26 | 3.4 | 2.94 | 3.27 | 3.1 | |
| Interest coverage | 142.4 | 259.55 | 212.77 | 201.85 | 122.85 | |
| Income quality | 1 | 1 | 1.39 | 1.14 | 0.7 | |
| Dividend Yield | 0 | 0 | 0.01 | 0.02 | 0.03 | |
| Payout ratio | 0 | 0.01 | 0.47 | 0.82 | 0.92 | |
| Sales general and administrative to revenue | -0.05 | 0.04 | -0.02 | 0.12 | -0.06 | |
| Research and developement to revenue | 0.1 | 0.04 | 0.05 | 0.06 | 0.04 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | |
| Capex to operating cash flow | -0.11 | -0.08 | -0.08 | -0.16 | -0.1 | |
| Capex to revenue | -0.02 | -0.02 | -0.03 | -0.06 | -0.02 | |
| Capex to depreciation | -0.8 | -0.71 | -0.95 | 0.72 | -0.85 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 13.6 | 14.77 | 14.54 | 14.22 | 17.73 | |
| ROIC | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | |
| Return on tangible assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.05 | |
| Graham Net | 7.4 | 8.09 | 7.95 | 8.57 | 9.34 | |
| Working capital | 7.75B | 8.45B | 8.32B | 8.87B | 9.64B | |
| Tangible asset value | 10.86B | 11.55B | 11.42B | 12.01B | 12.96B | |
| Net current asset value | 7.55B | 8.25B | 8.11B | 8.66B | 9.53B | |
| Invested capital | 0.04 | 0.03 | 0.05 | 0.06 | 0.12 | |
| Average receivables | 2.51B | 2.61B | 2.28B | 2.14B | 2.43B | |
| Average payables | 1.16B | 1.71B | 1.97B | 1.95B | 1.79B | |
| Average inventory | 415.54M | 444.6M | 514.45M | 560.99M | 540.44M | |
| Days sales outstanding | 84.31 | 87.45 | 89.55 | 97.2 | 82.16 | |
| Days payables outstanding | 260.47 | 401.91 | 432.84 | 487.19 | 246.52 | |
| Days of inventory on hand | 67.74 | 104.33 | 113.63 | 153.43 | 71.3 | |
| Receivables turnover | 1.07 | 1.03 | 1.01 | 0.93 | 1.1 | |
| Payables turnover | 0.35 | 0.22 | 0.21 | 0.18 | 0.37 | |
| Inventory turnover | 1.33 | 0.86 | 0.79 | 0.59 | 1.26 | |
| ROE | 0.05 | 0.06 | 0.06 | 0.05 | 0.07 | |
| Capex per share | -0.07 | -0.06 | -0.08 | -0.12 | -0.07 |
600566.SS Frequently Asked Questions
What is Hubei Jumpcan Pharmaceutical Co., Ltd. stock symbol ?
Hubei Jumpcan Pharmaceutical Co., Ltd. is a CN stock and trading under the symbol 600566.SS
What is Hubei Jumpcan Pharmaceutical Co., Ltd. stock quote today ?
Hubei Jumpcan Pharmaceutical Co., Ltd. stock price is $43.96 today.
Is Hubei Jumpcan Pharmaceutical Co., Ltd. stock public?
Yes, Hubei Jumpcan Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 6.8M
- Market Capitalization 38.35B
- Employee 5.23K
- CEO Mr. Fei Cao
- Headquarters Taixing,CN
- IPO Date 2001-08-22
-
Website
https://www.jumpcan.com 
Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis. The company was formerly known as Hubei Hongcheng General Machinery Co., Ltd and changed its name to Hubei Jumpcan Pharmaceutical Co., Ltd. in March 2015. Hubei Jumpcan Pharmaceutical Co., Ltd. is based in Taixing, China.
